To evaluate the clinical efficacy of Spray-Type Nasal Allergen Blocker as an adjuvant therapy for pediatric allergic rhinitis (AR).
Methods:
Eighty-two pediatric AR patients aged 4 to 14 years were included in this retrospective study and divided into 2 groups based on the treatments documented in their medical records: one treated with Mometasone Furoate Aqueous Nasal Spray (n = 38) and the other with a combination of a Spray-Type Nasal Allergen Blocker and Mometasone Furoate Aqueous Nasal Spray (n = 44).
Results:
After 4 weeks of treatment, the total effective rate, the serum levels of IFN-γ, TGF-β, nasal ventilation area, ciliary movement rate, and pediatric Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) scores were higher in the Combination group than in Mometasone group, while the Total Nasal Symptom Score (TNSS) and nasal resistance were lower in the Combination group (P < .05).
Conclusion:
Combination of Spray-Type Nasal Allergen Blocker and Mometasone Furoate Aqueous Nasal Spray exhibits promising results in the treatment of pediatric AR compared to Mometasone Furoate Aqueous Nasal Spray alone.
Subspecialty Group of Rhinology, Editorial Board of Chinese Journal of Otorhinolaryngology Head and Neck Surgery; Subspecialty Group of Rhinology, Society of Otorhinolaryngology Head and Neck Surgery, Chinese Medical Association. Chinese guideline for diagnosis and treatment of allergic rhinitis (2022, revision). Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2022;57:106-129.
2.
Subspecialty Group of Rhinology, Editorial Board of Chinese Journal of Otorhinolaryngology Head and Neck Surgery; Subspecialty Groups of Rhinology and Pediatrics, Society of Otorhinolaryngology Head and Neck Surgery, Chinese Medical Association. Guideline for diagnosis and treatment of pediatric allergic rhinitis (2022, revision). Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2022;57:392-404.
3.
MengYWangCZhangL.Advances and novel developments in allergic rhinitis. Allergy. 2020;75:3069-3076.
4.
SastreJMosgesR.Local and systemic safety of intranasal corticosteroids. J Investig Allergol Clin Immunol. 2012;22:1-12.
5.
WuXMFengYJZengCRWangMJ.Clinical observation of nasal spray allergen blocker combined with antihistamines in treatment of allergic rhinitis children. Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2020;34:60-63.
6.
NehrigJGrosseNHohenfeldIPHohlfeldJMBadorrekP.Efficacy and safety of a drug-free, barrier-forming nasal spray for allergic rhinitis: randomized, open-label, crossover noninferiority trial. Int Arch Allergy Immunol. 2023;184:111-121.
7.
LiYChengLChenXYangBWangD.Efficacy evaluation of a pollen blocker cream against dust-mite allergy: a multicenter, randomized, double-blind, placebo-controlled crossover trial. Am J Rhinol Allergy. 2015;29:e129-e133.
8.
Sirin KoseSAtakulGAsilsoySKaramanOUzunerNAnalO. Efficacy of allergen-blocker mechanical barrier gel on symptoms and quality of life in patients with allergic rhinitis. Eur Arch Otorhinolaryngol. 2019;276:729-734.
9.
ZhangYLanFZhangL.Update on pathomechanisms and treatments in allergic rhinitis. Allergy. 2022;77:3309-3319.
10.
JiaHZhangRLiangXJiangXBuQ.Regulatory effects of miRNA-126 on Th cell differentiation and cytokine expression in allergic rhinitis. Cell Signal. 2022;99:110435.
11.
BousquetJAntoJMBachertC, et alAllergic rhinitis. Nat Rev Dis Primers. 2020;6:95.
12.
BernsteinJABernsteinJSMakolRWardS.Allergic rhinitis: a review. JAMA. 2024;331:866-877.
13.
CourouxPGrosseNSalapatekAMGoyalYPfaarOHohenfeldIP.Barrier-forming, drug-free nasal spray reduces allergic symptoms induced by house dust mite allergen. Clin Transl Allergy. 2023;13:e12277.
14.
LangeBLukatKFRettigKHoltappelsGBachertC.Efficacy, cost-effectiveness, and tolerability of mometasone furoate, levocabastine, and disodium cromoglycate nasal sprays in the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2005;95:272-282.
15.
MeteranHBackerV.Mometasone furoate nasal spray for the treatment of asthma. Expert Opin Investig Drugs. 2016;25:999-1004.
16.
CasanovaJLMacMickingJDNathanCF.Interferon-gamma and infectious diseases: lessons and prospects. Science. 2024;384:eadl2016.
17.
DingHWangGYuZSunHWangL.Role of interferon-gamma (IFN-gamma) and IFN-gamma receptor 1/2 (IFNgammaR1/2) in regulation of immunity, infection, and cancer development: IFN-gamma-dependent or independent pathway. Biomed Pharmacother. 2022;155:113683.
18.
JiTLiH.T-helper cells and their cytokines in pathogenesis and treatment of asthma. Front Immunol. 2023;14:1149203.
19.
LiYZhouJRuiXZhouLMoX.PM2.5 exposure exacerbates allergic rhinitis in mice by increasing DNA methylation in the IFN-gamma gene promoter in CD4+T cells via the ERK-DNMT pathway. Toxicol Lett. 2019;301:98-107.
20.
YangJZhongWXueKWangZ.Epigenetic changes: an emerging potential pharmacological target in allergic rhinitis. Int Immunopharmacol. 2019;71:76-83.
21.
ElkoshiZ.TGF-beta, IL-1beta, IL-6 levels and TGF-beta/Smad pathway reactivity regulate the link between allergic diseases, cancer risk, and metabolic dysregulations. Front Immunol. 2024;15:1371753.
22.
DengZFanTXiaoC, et alTGF-beta signaling in health, disease, and therapeutics. Signal Transduct Target Ther. 2024;9:61.
23.
OuyangYMiyataMHatsushikaK, et alTGF-beta signaling may play a role in the development of goblet cell hyperplasia in a mouse model of allergic rhinitis. Allergol Int. 2010;59:313-319.
24.
NathanRAEcclesRHowarthPHSteinsvagSKTogiasA.Objective monitoring of nasal patency and nasal physiology in rhinitis. J Allergy Clin Immunol. 2005;115:S442-S459.
25.
HossenbaccusLLintonSGarveySEllisAK.Towards definitive management of allergic rhinitis: best use of new and established therapies. Allergy Asthma Clin Immunol. 2020;16:39.
26.
QiuCFengD.Efficacy and anti-inflammatory analysis of glucocorticoid, antihistamine and leukotriene receptor antagonist in the treatment of allergic rhinitis. World J Clin Cases. 2023;11:6725-6732.
